ANTX — AN2 Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1880438 ·
Last close
$4.23
Market Cap
$160.50M
52W High
$7.19
52W Low
$1.00
ADV30
287,052
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -8,670,000 | -7,957,000 | 81,955,000 | 20,207,000 | 6,445,000 |
| Jun 2026 | 0 | — | -8,904,000 | -8,185,000 | 81,676,000 | 44,318,000 | 5,755,000 |
| Mar 2026 | 0 | — | -10,551,000 | -10,028,000 | 87,491,000 | 53,487,000 | 5,732,000 |
| Dec 2025 | 0 | — | -9,316,000 | -8,710,000 | 61,950,000 | 19,941,000 | 8,890,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-30,409,000
Investing CF
$-12,637,000
Financing CF
$45,250,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-267,120,000
Inventory
—
Receivables
—
ST Investments
$44,193,000
EBIT TTM
$-37,441,000
Pretax Income TTM
$-34,880,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -38,109,000 | -35,174,000 | 61,950,000 | 8,890,000 | 53,060,000 | -29,834,000 |
| Dec 2024 | 0 | -54,554,000 | -51,321,000 | 92,087,000 | 10,238,000 | 81,849,000 | -49,257,000 |
| Dec 2023 | 0 | -69,635,000 | -64,732,000 | 138,744,000 | 14,043,000 | 124,701,000 | -53,288,000 |
| Dec 2022 | 0 | -42,262,000 | -40,956,000 | 102,560,000 | 7,188,000 | 95,372,000 | -33,462,000 |
TTM Snapshot
Revenues TTM
$2,535,000
NetIncome TTM
$-36,276,000
OpCashFlow TTM
—
Assets (Latest)
$81,676,000
Forward EPS
$-0.77
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABEO | ABEONA THERAPEUTICS INC. | $160.27M | $2.60 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $162.10M | $3.20 | — |
| PRQR | ProQR Therapeutics N.V. | $162.29M | $1.15 | — |
| YARW | Yarrow Bioscience, Inc. | $163.04M | $14.21 | — |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $155.69M | $1.94 | — |
News headlines (Yahoo Finance, 1h cache)
AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights
2026-11-09 12:30 · Yahoo
AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London
2026-11-04 21:00 · Yahoo
AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
2026-11-04 12:00 · Yahoo
AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
2026-11-02 12:00 · Yahoo
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
2026-10-23 21:00 · Yahoo
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
2026-10-21 11:00 · Yahoo
AN2 Therapeutics to Participate at Upcoming Investor Conferences
2026-10-20 20:13 · Yahoo
GSK (LSE:GSK) The Latest Update Raises A Bigger Question
2026-09-30 11:13 · Yahoo
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
2026-09-28 11:00 · Yahoo
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
2026-09-16 21:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.